Telix Pharmaceuticals Limited (NASDAQ:TLX) Receives Average Recommendation of “Moderate Buy” from Analysts

Telix Pharmaceuticals Limited (NASDAQ:TLX) has received a consensus recommendation of “Moderate Buy” from the nine ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $21.00.

Several research analysts have recently weighed in on TLX shares. Canaccord Genuity Group raised Telix Pharmaceuticals to a “strong-buy” rating in a research report on Monday, October 6th. Royal Bank Of Canada assumed coverage on Telix Pharmaceuticals in a research note on Monday, December 15th. They issued a “hold” rating on the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, October 8th. Citigroup started coverage on shares of Telix Pharmaceuticals in a report on Thursday, September 18th. They issued a “buy” rating and a $22.00 price objective on the stock. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a report on Monday, December 22nd.

Hedge Funds Weigh In On Telix Pharmaceuticals

Several hedge funds have recently modified their holdings of TLX. Millennium Management LLC bought a new position in shares of Telix Pharmaceuticals in the third quarter valued at about $1,883,000. Pier Capital LLC bought a new stake in shares of Telix Pharmaceuticals during the 2nd quarter worth about $3,037,000. Portland Investment Counsel Inc. acquired a new position in Telix Pharmaceuticals in the 3rd quarter valued at about $1,225,000. Lazard Asset Management LLC acquired a new position in Telix Pharmaceuticals in the 3rd quarter valued at about $1,097,000. Finally, Russell Investments Group Ltd. bought a new position in Telix Pharmaceuticals in the 2nd quarter valued at about $975,000.

Telix Pharmaceuticals Stock Down 0.9%

TLX opened at $8.03 on Friday. Telix Pharmaceuticals has a 12 month low of $7.72 and a 12 month high of $30.36. The firm’s fifty day simple moving average is $9.56 and its 200 day simple moving average is $11.60.

About Telix Pharmaceuticals

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.